LES LABORATOIRES SERVIER

In News

Servier and n-Lorem Foundation join forces to advance research in rare neurodevelopmental disorders - Servier

Servier - Jun 10, 2026

Insilico Medicine Announces US$888 Million Multi-Year Collaboration with Servier for Drug Discovery and Development in Oncology - Insilico Medicine

Insilico Medicine - Jan 04, 2026

Servier completes the acquisition of Day One Biopharmaceuticals - PR Newswire

PR Newswire - Apr 23, 2026

Edgewise Therapeutics announces sale of Sevasemten to Servier for up to $2.65 bln - marketscreener.com

marketscreener.com - Jun 01, 2026

Servier Acquires Day One Biopharmaceuticals for $2.5B, Betting on Tovorafenib and the Pediatric Glioma Frontier - Oncodaily

Oncodaily - Mar 12, 2026

Edgewise Therapeutics (EWTX) to sell sevasemten business to Servier for up to $2.65B - Stock Titan

Stock Titan - Jun 01, 2026

Servier to widen rare cancer offerings with $2.5B buyout of Day One and glioma drug Ojemda - Fierce Pharma

Fierce Pharma - Mar 06, 2026

Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B - statnews.com

statnews.com - Mar 06, 2026

Servier and Day One Biopharmaceuticals announce acquisition to expand Servier’s rare oncology portfolio - Servier

Servier - Mar 06, 2026

BC Partners to Acquire Servier’s Generic Drug Unit Biogaran - Bloomberg.com

Bloomberg.com - Jul 30, 2025

Servier and IDEAYA Biosciences Partner to Bring Darovasertib, a Promising Uveal Melanoma Treatment, to Patients Worldwide - PR Newswire

PR Newswire - Sep 02, 2025

Acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business - Servier

Servier - Jun 01, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment